

Client: ACCESS MEDICAL LABS, 0 1 Patient: PATIENT, TEST

Phone: Age:24 Sex: F 5151 CORPORATE WAY () -DOB. 01/01/2000 JUPITER, FL 33458

Address 1:

Fasting: N

Address 2:

Phys: SARA, ALAN (561) 745-1233 City: State: Zip: Page:1

Acc# 004579161 Coll. Date: 02/23/24 Recv. Date: 02/23/24 Print Date: 03/08/24 Chart# Coll. Time: 00:00 AM Recv. Time:02:11 PM Print Time: 09:01 02/23/24 14:52 02/28/24 First reported on: Final report date:

Report Status: FINAL

Test Name	Results	Reference Range	Units
COMPLETE BLOOD COUNT			
WHITE BLOOD CELL	5.9	3.9 - 11.4	K/ul
RED BLOOD CELL	4.67	3.80 - 5.50	M/ul
HEMOGLOBIN	14.1	11.5 - 15.2	g/dl
HEMATOCRIT	48.8	38.0 - 51.0	%
MCV	105 н	83 - 103	fl
MCH	30.2	26.0 - 34.0	pg
MCHC	28.9 L	29.5 - 35.5	g/dl
RDW	13.2	11.0 - 15.5	%
PLATELET COUNT	243	140 - 400	k/ul
MPV	11.8 н	7.5 - 11.6	fl

The reference range reflects change to Siemens Advia 2120i instrumentation.

4.5

105

25

3.5 - 5.1

20 - 31

100 - 110

mmol/L

mmol/L

mmol/L

AUTOMATED DIFFERENTIAL

POTASSIUM

CHLORIDE

CO2

AUTOMATED DITTERENTIAL			
DIFFERENTIAL			
Neutrophil %	62.5	38.0 - 75.0	%
Lymphocyte %	30.1	15.0 - 49.0	%
Monocyte %	3.9	2.0 - 13.0	%
Eosinophil %	2.1	0.0 - 8.0	%
Basophil %	1.3	0.0 - 2.0	%
Neutrophil #	3.7	1.6 - 8.4	K/ul
Lymphocyte #	1.8	1.0 - 3.6	K/ul
Monocyte #	0.2	0.0 - 0.9	K/ul
Eosinophil #	0.1	0.0 - 0.6	K/ul
Basophil #	0.1	0.0 - 0.2	K/ul
HEMATOLOGY TESTS			
Reticulocyte Count	0.9	0.5 - 1.9	%
GENERAL CHEMISTRY			
GLUCOSE	100	65 - 100	mg/dl
BUN	10	6 - 20	mg/dl
CREATININE, SERUM	1.5 н	0.5 - 1.0	mg/dl
SODIUM	145	136 - 145	mmol/L



Client: ACCESS MEDICAL LABS, 0 1 Patient: PATIENT, TEST

5151 CORPORATE WAY

JUPITER, FL 33458

Phone: () - DOB. 01/01/2000 Age:24 Sex: F

Address 1: Fasting: N

Address 2:

Phys: SARA, ALAN (561) 745-1233 City: State: Zip: Page:2

 Acc# 004579161
 Coll. Date: 02/23/24
 Recv. Date: 02/23/24
 Print Date: 03/08/24

 Chart#
 Coll. Time: 00:00 AM
 Recv. Time:02:11 PM
 Print Time: 09:01

First reported on: 02/23/24 14:52 Final report date: 02/28/24

Report Status: FINAL

Test Name	Results	Reference Range	Units
GENERAL CHEMISTRY (Continued)			
CALCIUM	9.0	8.3 - 10.6	mg/dl
TOTAL PROTEIN	9.0 н	5.7 - 8.2	g/dl
ALBUMIN	4.5	3.2 - 4.8	g/dl
GLOBULIN	4.5 н	2.2 - 3.7	g/dl
BILIRUBIN, TOTAL	0.2 L	0.3 - 1.2	mg/dl
ALKALINE PHOSPHATASE	10 L	37 - 98	U/L
ALT	15	0 - 48	U/L
AST	15	0 - 32	U/L
Albumin/Globulin Ratio	1.0	0.8 - 2.0	
BUN/CREAT RATIO	N/A	7.3 - 21.7	
GFR, estimated	45		ml/min

If African-American, result is: 55

Calculation of estimated GFR is based on the MDRD Study prediction equation

****Five Stages of Chronic Kidney Disease****

Stage	*GFR Level*	*Description*
Stage 1	90 ml/min or more	Healthy Kidneys or Kidney
		damage with normal or high GFR
Stage 2	60 to 89 ml/min	Kidney damage and mild decrease
		in GFR
Stage 3	30 to 59 ml/min	Moderate decrease in GFR
Stage 4	15 to 29 ml/min	Severe decrease in GFR
Stage 5	< 15 ml/min	Kidney failure, or on dialysis

DIABETES EVALUATION

HEMOGLOBIN A1C 4.0 < 5.7 9

Diagnosis

Normal

Prediabetes

Diabetes

HbA1c Level

5.7 - 6.4 %

= or > 6.5 %

Having prediabetes is a Risk Factor for getting type 2 diabetes. Within the prediabetes range(5.7-6.4), the higher the HbAlc,the greater the risk of diabetes. HbAlc target for diabetics depend on their history and health.

INSULIN 2.55 L 3.0 - 25.0 uIU/ml

IRON/ANEMIA EVALUATION

IRON 45 L 50 - 170 ug/dl



Client: ACCESS MEDICAL LABS, 0 1 Patient: PATIENT, TEST

5151 CORPORATE WAY Phone: () -DOB. 01/01/2000 Age:24 Sex: F JUPITER, FL 33458 Address 1: Fasting: N

Address 2:

Phys: SARA, ALAN (561) 745-1233 City: State: Zip: Page:3

Acc# 004579161 Coll. Date: 02/23/24 Recv. Date: 02/23/24 Print Date: 03/08/24 Chart# Coll. Time: 00:00 AM Recv. Time:02:11 PM Print Time: 09:01

First reported on: 02/23/24 14:52 Final report date: 02/28/24

Report Status: FINAL

Test Name	Results	Reference Range	Units
IRON/ANEMIA EVALUATION (Continued)		•	
TOTAL IRON-BIND. CAPACITY	350	250 - 425	ug/dl
% IRON SATURATION	13 L	15 - 50	%
FERRITIN	100	7.3 - 270.7	ng/ml
VITAMIN B12	>2000 H	211 - 911	pg/ml
FOLATE, SERUM	12.5	5.38 - 24.0	ng/ml
CORONARY RISK			
TRIGLYCERIDES	150 н	<150	mg/dl
CHOLESTEROL, TOTAL	200 н	<200	mg/dl
HDL CHOLESTEROL	65	>40	mg/dl
LDL CHOLESTEROL, calc	109 н	<100	mg/dl
CHOL/HDL RATIO	3.1	<4.4	
	The higher the Ratio,	the higher CHD ris	k.

CRP, Cardio 12.5 H <3 mg/L

Risk of Cardiovasular Disease

Low Risk CRP < 1.0mg/L CRP 1.0 - 3.0 Medium Risk mg/L High Risk CRP > 3.0

Results verified by repeat analysis and dilution.

HOMOCYSTEINE 17.5 н 4.5 - 15.0 umol/L

Ideal level <8.0 umol/L</pre>

Vitamin D,25-OH,Total 50 30 - 100 ng/ml

Notes:

Therapy is based on the measurement of Total Vitamin D (25-OH). Most experts agree that Vitamin D deficiency should be = or < 20 ng/ml. Vitamin D insufficiency is recognized as 21 - 29 ng/ml.

The preferred level for Vitamin D (25-OH)is recommended to be 30 - 100 ng/ml.



Client: ACCESS MEDICAL LABS, 0 1 Patient: PATIENT, TEST

5151 CORPORATE WAY

JUPITER, FL 33458

Phone: () - DOB. 01/01/2000 Age:24 Sex: F

Address 1: Fasting: N

Address 2:

Phys: SARA, ALAN (561) 745-1233 City: State: Zip: Page:4

 Acc# 004579161
 Coll. Date: 02/23/24
 Recv. Date: 02/23/24
 Print Date: 03/08/24

 Chart#
 Coll. Time: 00:00 AM
 Recv. Time:02:11 PM
 Print Time: 09:01

First reported on: 02/23/24 14:52 Final report date: 02/28/24

Report Status: FINAL

Test Name Results Reference Range Units

CORONARY RISK (Continued)

Vitamin D > 150 ng/ml is considered potentially toxic.

ENDOCRINE EVALUATION

PROGESTERONE 15 ng/mL

Female Reference Ranges

Follicular phase 0.00 - 1.40 ng/mL Luteal phase 3.34 - 25.56 ng/mL Mid-luteal phase 4.44 - 28.03 ng/mL Postmenopausal 0.00 - 0.73 ng/mL

Pregnant

First trimester 11.22 - 90.00 ng/mL Second trimester 25.55 - 89.40 ng/mL Third trimester 48.40 - 422.5 ng/mL

PREGNENOLONE, LC/MS/MS

Effective 3/13/17, Pregnenolone is performed in-house on LC/MS/MS.

67.2

2.5 - 75.0

ng/dL

ESTRONE (E1), LC/MS/MS 65.1 17.0 - 200.0 pg/ml ESTRADIOL (E2) 52 pg/mL

Female Reference Ranges

Menstruating females (by day in cycle relative to LH peak)

Follicular Phase (-12 to -4 days) 19.5 - 144.2 pg/mL Mid Cycle Peak (-3 to +2 days) 63.9 - 356.7 pg/mL Luteal Phase (+4 to +12 days) 55.8 - 214.2 pg/mL Post Menopausal (untreated) 0.0 - 32.2 pg/mL

ESTRIOL (E3), LC/MS/MS 0.102 <0.20 ng/ml
DHEA-SULFATE 20.1 L 25.9 - 460.2 ug/dl
DIHYDROTESTOSTERONE LC/MS 87.6 H <30.0 ng/dL



Client: ACCESS MEDICAL LABS, 0 1 Patient:

5151 CORPORATE WAY

JUPITER, FL 33458

Patient: PATIENT, TEST

Phone: () -

DOB. 01/01/2000

Age:24 Sex: F

Address 1: Address 2:

Phys: SARA, ALAN

(561) 745-1233

City:

State:

Zip:

Page:5

Fasting: N

Acc# 004579161 Chart#

First reported on:

Coll. Date: 02/23/24 Coll. Time: 00:00 AM 02/23/24 14:52 Recv. Date: 02/23/24 Recv. Time:02:11 PM Final report date: Print Date: 03/08/24 Print Time: 09:01

02/28/24

Report Status: FINAL

rest name	Results	Reference Range	Units	
ENDOCRINE EVALUATION (Continued)	<u> </u>			

ENDOCRINE EVALUATION (Continued)

TESTOSTERONE, TOTAL

45

6 - 82

ng/dl

Female Reference Ranges

Premenopausal 9 - 48 ng/dL Postmenopausal <7 - 46 ng/dL

SEX HORMONE BIND GLOBULIN

35

nmol/L

Female Reference Ranges

Premenopausal 11 - >180.00 nmol/L Postmenopausal 23 - 159 nmol/L

TESTOSTERONE, FREE CORTISOL

0.8 4.5 0.2 - 2.6

ng/dl ug/dl

Normal individuals

Morning am 7-9: 5.2 - 22.5 ug/dL Afternoon pm 3-5: 3.4 - 16.8 ug/dL

Lab Developed Testing

Serum Pregnenolone, DHT, Estrone, Estriol, RT3 and CO-Q10 were developed and their performance characteristics determined by Access Medical Laboratories.

It has not been cleared or approved by the FDA.

The laboratory is regulated under CLIA and qualified to perform high-complexity testing. These tests are used for clinical purposes. It should not be regarded as investigational or for research.



Director: Alan Sara, M.D

Client: ACCESS MEDICAL I	ABS, 0 1		Patient: PATIENT, TES	ST		
5151 CORPORATE W	AY		Phone: () -	DOB. 01/01/2	.000	Age:24 Sex:F
JUPITER, FL 33458			Address 1:			Fasting: N
,			Address 2:			Z .
Phys: SARA, ALAN	(561) 745-	1233	City:	State:	Zip	Page:6
Acc# 004579161	Coll. Date: 02/23/24		Recv. Date: 02/23/24	Print Date: 0	03/08/2	4
Chart#	Coll. Time: 00:00 AM		Recv. Time:02:11 PM	Print Time: 0	9:01	
First reported on:	02/23/24 14:52		Final report date:	02/28/24		
Report Status: FINAL						
Report Status: FINAL Test Name			Results	Reference Rar	nge	Units
-	ATION (Continued)		Results	Reference Rar	nge	Units
Test Name	ATION (Continued)		Results	Reference Rar	nge	Units
Test Name	ATION (Continued)		Results	Reference Rar	nge	Units
Test Name	ATION (Continued)	E	Results ND OF REPORT	Reference Rar	nge	Units
Test Name	ATION (Continued)	EI		Reference Rar	nge	Units

